Stock AUGX AUGMEDIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Augmedix, Inc.

Equities

AUGX

US05105P1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
1.12 USD -4.27% Intraday chart for Augmedix, Inc. -8.94% -80.85%
May. 14 Maxim Downgrades Augmedix to Hold From Buy MT
May. 14 B. Riley Adjusts Price Target on Augmedix to $3 From $5.50, Keeps Buy Rating MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Business Support Services

1st Jan change Capi. Investor Rating ESG Refinitiv
AUGMEDIX, INC. Stock Augmedix, Inc.
-80.85% 54.59M -
CINTAS CORPORATION Stock Cintas Corporation
+15.50% 70.63B
B+
JACOBS SOLUTIONS INC. Stock Jacobs Solutions Inc.
+6.72% 17.34B
B+
RB GLOBAL, INC. Stock RB Global, Inc.
+11.94% 13.76B
B-
BUREAU VERITAS SA Stock Bureau Veritas SA
+22.43% 13.6B
A-
INTERTEK GROUP PLC Stock Intertek Group plc
+17.99% 10.15B
B-
TELEPERFORMANCE SE Stock Teleperformance SE
-18.71% 6.84B
C
GENPACT LIMITED Stock Genpact Limited
-2.54% 6.09B
A-
MAXIMUS, INC. Stock Maximus, Inc.
+2.69% 5.24B
B-
EXLSERVICE HOLDINGS, INC. Stock ExlService Holdings, Inc.
+0.32% 5.03B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AUGX Stock
  4. Ratings Augmedix, Inc.